61.3 The Word "Demyelinating" — What It Means
64Tremor in CIDP
71.4 Chronic vs. Acute: How CIDP Differs from GBS
65Muscle Spasms and Cramps
81.5 Why CIDP Is Often Underdiagnosed
66Anxiety in CIDP
9Chapter 2: A History of CIDP
677.9 Comprehensive Treatment Comparison
102.1 Early Observations of Peripheral Nerve Disease
687.10 Treatment Algorithm: Step-by-Step Overview
112.2 Guillain, Barré, and Strohl (1916)
69Chapter 8: Living with CIDP
122.3 The 1950s and 1960s: A Chronic Form Emerges
708.1 Rehabilitation: Rebuilding Strength and Function
132.4 Peter Dyck and the Formal Definition (1975)
718.2 Managing Fatigue
142.5 The 1980s–1990s: New Treatments and Confirmation
728.3 Psychological Impact and Mental Health
152.6 The 2000s–2010s: Subtypes and Biological Targets
738.4 Nutrition and General Wellness
162.7 The 2020s: Targeted Therapies and Personalized Medicine
748.5 Monitoring, Follow-Up, and Reassessing Treatment Need
17Chapter 3: Epidemiology — Who Gets CIDP?
758.6 Prognosis: What Can Patients Expect?
183.1 How Common Is CIDP?
76Chapter 9: Special Populations and Associated Conditions
193.2 Age and Sex Distribution
779.1 CIDP and Diabetes Mellitus
203.3 Geographic and Ethnic Distribution
789.2 CIDP in Children (Pediatric CIDP)
213.4 Risk Factors and Associated Conditions
799.3 CIDP and Monoclonal Gammopathy (MGUS and Related Disorders)
223.5 Economic and Social Burden
809.4 CIDP-Related Nodopathies: A Distinct Category
23Chapter 4: Pathology — What Happens Inside the Nerve?
819.5 CIDP in Pregnancy
244.1 The Immune Attack: An Overview
829.6 CIDP and COVID-19
254.2 The Blood-Nerve Barrier
83Chapter 10: Research and the Future of CIDP
264.3 The Node of Ranvier: Architecture and Vulnerability
8410.1 The Search for Reliable Biomarkers
274.4 Demyelination, Remyelination, and Onion Bulbs
8510.2 Precision Medicine: Matching Treatment to Biology
284.5 What the Nerve Biopsy Shows
8610.3 Reducing Treatment Burden and Achieving Remission
294.6 Key Antibody Targets: A New Era of Understanding
8710.4 Clinical Trials: How Patients Can Participate
304.7 Recognized Clinical Subtypes of CIDP
8810.5 International Collaboration and Patient Registries
31Chapter 5: Symptoms — What Does CIDP Feel Like?
89References and Further Reading
325.1 The Typical Presentation
90Foundational and Historical Works
335.2 Motor Symptoms — Weakness and Movement Problems
91Diagnostic Guidelines
345.3 Sensory Symptoms — Abnormal Feelings
92Key Treatment Trials
355.4 Balance and Gait Problems
93Emerging Therapies — 2024 to 2026
365.5 Less Common Symptoms
94Pathophysiology and Antibody Subtypes
375.6 Clinical Courses Over Time
95Reviews and Systematic Analyses
385.7 Impact on Daily Life and Quality of Life
96Patient Resources (Current as of April 2026)
39Chapter 6: Diagnosis — How Is CIDP Identified?
97Glossary of Key Terms
406.1 Why Diagnosis Is Challenging
98Appendix A: Patient Symptom and Treatment Diary: Treatment Log
416.2 Clinical History and Neurological Examination
99Appendix B: Understanding Your Nerve Conduction Study Report: Key Terms Explained
426.3 Nerve Conduction Studies (NCS) and Electromyography (EMG)
100Appendix C: Questions to Ask Your Neurologist
436.4 Cerebrospinal Fluid (CSF) Analysis
101At the Time of Diagnosis
446.5 MRI of the Spine and Peripheral Nerves
102At Follow-Up Appointments
456.6 Blood Tests
103About Daily Life
466.7 Nerve Biopsy
104Appendix D: CIDP Rating Scales Used in Research and Practice
476.8 Diagnostic Certainty Levels and the Treatment Trial: 6.8.1 How Many Nerves Must Be Abnormal? The 2021 NCS Demyelination Criteria
105MRC Sum Score (Motor Strength)
48Chapter 7: Treatment — Managing and Treating CIDP
106I-RODS (Inflammatory Rasch-Built Overall Disability Scale)
497.1 The Goals and Philosophy of CIDP Treatment
107Overall Neuropathy Limitations Scale (ONLS)
507.2 First-Line Treatments
108Modified Rankin Scale (mRS)
517.2.1 Corticosteroids (Steroids)
109Patient Global Impression of Change (PGIC)
527.2.2 Intravenous Immunoglobulin (IVIG)
110Appendix E: Medication Reference Card
537.2.3 Plasma Exchange (Plasmapheresis)
111Appendix F: Resources and Support Organizations
547.3 Subcutaneous Immunoglobulin (SCIg): Independence and Convenience
112Patient and Family Support
557.3.1 Conventional SCIg (Hizentra, Cuvitru)
113Clinical and Research Information
567.3.2 HyQvia (Facilitated SCIg / fSCIg)
114Disability and Practical Support (United States)
577.4 The 2023 Breakthrough: Efgartigimod Alfa (Vyvgart Hytrulo)
115Mental Health and Wellness
58The Science: How FcRn Inhibition Works
